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ABSTRACT
The selective degradation of mutated mitochondrial
DNA (mtDNA) molecules is a potential strategy to
re-populate cells with wild-type (wt) mtDNA mole-
cules and thereby alleviate the defective mitochon-
drial function that underlies mtDNA diseases. Zinc
finger nucleases (ZFNs), which are nucleases con-
jugated to a zinc-finger peptide (ZFP) engineered to
bind a specific DNA sequence, could be useful for
the selective degradation of particular mtDNA
sequences. Typically, pairs of complementary ZFNs
are used that heterodimerize on the target DNA
sequence; however, conventional ZFNs were inef-
fective in our system. To overcome this, we created
single-chain ZFNs by conjugating two FokI nuclease
domains, connected by a flexible linker, to a ZFP with
an N-terminal mitochondrial targeting sequence.
Here we show that these ZFNs are efficiently trans-
ported into mitochondria in cells and bind mtDNA in
a sequence-specific manner discriminating between
two 12-bplong sequences thatdiffer by a singlebase
pair. Due to their selective binding they cleave
dsDNA at predicted sites adjacent to the mutation.
When expressed in heteroplasmic cells containing a
mixture of mutated and wt mtDNA these ZFNs selec-
tively degrade mutated mtDNA, thereby increasing
the proportion of wt mtDNA molecules in the cell.
Therefore, mitochondria-targeted single-chain ZFNs
are a promising candidate approach for the treat-
ment of mtDNA diseases.
INTRODUCTION
One of the main functions of mitochondria is to provide
the cell with energy in the form of ATP; however,
mitochondria also play a role in other important cellular
processes such as Fe-S cluster biosynthesis, calcium homo-
eostasis, apoptosis or tumorigenesis. Mammalian mito-
chondria have their own small, circular, 16.5-kb genome
that encodes two rRNAs, 22 tRNAs and 13 subunits of
the oxidative phosphorylation machinery. Correct expres-
sion of mitochondrial DNA (mtDNA) is essential for
mitochondrial function; therefore, mutation to mtDNA
can have severe consequences for the cell by disrupting
oxidative phosphorylation. Currently, more than 100
point mutations and large-scale rearrangements in the
human mtDNA are known to be associated with a wide
spectrum of clinical manifestations, ranging from pro-
gressive muscle weakness to fatal infantile diseases (1,2).
There are no eﬀective treatments for diseases caused by
mtDNAmutation,inpartduetothediﬃcultyofexpressing
exogenous nucleic acids within mitochondria; conse-
quently, alternative approaches to the treatment of these
diseases have been sought (3,4). One approach is to use the
fact that each cell harbours hundreds of mtDNA molecules
(1), so that deleterious mtDNA mutations commonly co-
exist in the same cell with wild-type (wt) mtDNA, a
phenomenon called heteroplasmy. In heteroplasmic cells,
the phenotype of a pathogenic mtDNA mutation is
determined by the ratio of mutant and wt genomes, and
pathologyisonlyobservedaboveathresholdproportionof
mutated mtDNAs (5). As cells have a tendency to maintain
a ﬁxed number of mtDNA molecules (6), one treatment
optionistheselective elimination ofmutated mtDNA, thus
allowing the cell to re-populate itself with wt mtDNA,
thereby correcting the defective phenotype (7). This has
been achieved by targeting the restriction endonuclease
(RE) SmaI or XmaI to mitochondria in cells in culture,
where it selectively cleaved a unique site created in mtDNA
by the m.8993T>G mutation underlying the mtDNA
diseases neurogenic muscle weakness, ataxia and retinitis
pigmentosa (NARP) and maternally inherited Leigh’s
syndrome (MILS) (8,9). Similarly, in a heteroplasmic
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one with two PstI recognition sites and another with none,
mitochondrial expression of the PstI restriction enzyme
signiﬁcantly depleted the haplotype with two PstI sites
(10). This strategy can also be applied in vivo, as was shown
in a heteroplasmic mouse model containing the BALB
and NZB mtDNA haplotypes, where only the BALB
haplotype has a recognition site for cleavage by the ApaLI
RE (11). Mice transfected with mitochondrially targeted
ApaLI showed a rapid shift in heteroplasmy toward the
NZB variant in muscle and brain (11). Furthermore, the
same mouse system was used to verify that mitochondrially
expressed REs could shift heteroplasmy when a mutation
created a new restriction site in addition to the ones
normally present in the wt mtDNA (12).
These studies show that targeting mutated mtDNA
molecules for degradation has potential as a therapeutic
strategy. However, the use of natural REs limits its
application to those sequences created by a pathological
mutation that do not occur in wt mtDNA, and for which
an RE exists. One way around this constraint is to develop
sequence-speciﬁc nucleases that can be designed to cleave
any target sequence. Zinc ﬁnger technology allows the
engineering of zinc-ﬁnger proteins (ZFPs) that can bind
any predetermined DNA sequence (13). Fusing a partic-
ular ZFP to a nuclease domain creates a zinc-ﬁnger
nuclease (ZFN) that can cleave DNA adjacent to the
speciﬁc ZFP-binding site, thus providing virtually uni-
versal sequence speciﬁcity for DNA cleavage (14,15). The
nuclease domain generally used in ZFNs is the cleavage
domain of the type IIs restriction enzyme FokI, which
requires dimerization to cleave double-stranded DNA
(14). To achieve dimerization, pairs of ZFNs are used that
bind to adjacent sites on complementary DNA strands
spanning the target sequence, thus allowing the FokI
catalytic domains to cleave the DNA (16). Such custo-
mized ZFN technology has been used with human cells in
culture to drive site-speciﬁc gene correction and gene
addition via homologous recombination stimulated by
double-strand breaks to nuclear DNA (17,18).
Therefore, targeting ZFNs to mitochondria is an
appealing prospect to selectively deplete mutated mtDNA
sequences from heteroplasmic cells. In earlier work we
developed an eﬃcient method to deliver engineered ZFPs
to mitochondria and showed that zinc ﬁnger technology
can be used to target and alter mtDNA in a sequence-
speciﬁc manner (19). The selective binding of
mitochondria-speciﬁc ZFPs to mtDNA was exempliﬁed
by targeting the m.8993T>G mutation, which causes two
mitochondrial diseases, NARP and MILS. In the present
article, we report targeting the same mtDNA m.8993T>G
mutation using a ZFN. In applying ZFN technology to
mitochondria, we initially used conventional pairs of
heterodimeric ZFNs; however, we were unable to ﬁnd
suitable pairs of ZFNs for our speciﬁc mtDNA target (see
Supplementary Data). Therefore, we extended the ZFN
approach by developing a novel, single-chain ZFN. This
arrangement proved eﬀective in selectively cleaving
mutated, but not wt, mtDNA in cells. Here, we report
on the development and application of mitochondria-
targeted, single-chain ZFNs.
MATERIALS AND METHODS
Engineering ZFPsfor targeting human mtDNA
A number of potential target sites for binding ZFPs have
been identiﬁed in mtDNA. These include sites in the non-
coding region of the wt mtDNA as well as sequences
containing point mutations involved in the genetic
disorders (e.g. NARP m.8993T>G). The potential ZFPs
that bind to these targets have been assembled from the
archives of pre-selected modules by Sangamo BioSciences
Inc., Richmond, CA, USA (20) and are based on Zif268
randomized libraries described by Isalan et al. (21). DNA-
binding domains were engineered either as 1 4 zinc ﬁnger,
where individual zinc ﬁngers are connected via canonical
TGEKP linkers (22) (e.g. NARPd) or as a 2   two-ﬁnger
design (23) (e.g. NARPa or NARPb). The ZFPs were then
tested for their ability to selectively bind their target
sequences. The protein sequence of the ZFP targeting the
m.8993T>G mutation is given in Supplementary Figure 1.
The ZFP targeting the human mitochondrial non-coding
region is clone 18 as shown in Figure 1 and Supplementary
Figure 1 of our earlier publication (19).
Construction ofZFN expression vectors
The DNA encoding appropriate engineered zinc ﬁnger
peptideswas modiﬁed byPCR tointroduce theHA epitope
tag (YPYDVPDYA) to the C-terminus of the ZFP and
ﬂanked with unique XhoI (50) and EcoRI (30) restriction
sites. These were joined with PCR-ampliﬁed DNA
fragments ﬂanked with unique XbaI (50) and XhoI (30)
restriction sites, which encoded the 51-aa mitochondrial
targeting sequence (MTS) from human ATP synthase F1b
subunit (denoted F). The nuclear export signal (NES) was
added by PCR-ampliﬁcation of DNA fragments encoding
F-ZFP and epitope tag using 50 F-speciﬁc primer contain-
ing XbaI restriction site and a 30 epitope tag-speciﬁc primer
containing additional NES coding sequence and a BamHI
siteaddedattheextreme30 end.TheNES usedherewasthe
one from theNS2 protein of Minute Virusof Mice (VDEM
TKKFGTLTIHDTEK) (24). The resulting F-ZFP-NES
XbaI–BamHI fragments were cloned into XbaI and
BamHI sites of pcDNA3.1(–) (Invitrogen, Paisley,
Renfrewshire, UK). The F-ZFP-NES constructs were
used for in vitro binding tests to verify the speciﬁcity of
the ZFPs as described (19).
In order to construct the F-ZFP-Fok constructs
(ZFN monomers) the FokI catalytic domain (amino acids
388–583) was fused at the C-terminus of F-ZFP-NES via a
17-aa-long ﬂexible linker having the following sequence
[SGGGG]3SS in a two-part PCR reaction using four
primers. The ampliﬁed DNA fragments ﬂanked with
unique XbaI (50) and BamHI (30) restriction sites were
cloned into pcDNA3.1(–), pTRACER/CMV/BGH
(Invitrogen) or pIRESpuro/EF1a (Clontech-Takara Bio
Europe, Saint-Germain-en-Laye, France).
In order to create the single-chain quasi-dimeric ZFNs
the second FokI domain was fused at the C-terminus of the
F-ZFP-Fok constructs via the following ﬂexible linkers:
(i) 18 aa: SSGGGGSGGGGSGGGGSG
(ii) 22 aa: SSGGGGSGGGGSGGGGSGGGGS
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GGGS
(iv) 32 aa: SSGGGGSGGGGSGGGGSGGGGSGGGG
SGGGGS
(v) 35 aa: SSGGGGSGGGGSGGGGSGSSGGGGSG
GGGSGGGGS
(vi) 40 aa: SSGGGGSGGGGSGGGGSGGSGGGSSG
GGGSGGGGSGGGGS
The second domain of FokI was introduced in a two-
part PCR reaction using four primers and the entire
construct encoding F-ZFP-Fok-linker-Fok was cloned
between XbaI (50) and BamHI (30) restriction sites into
pcDNA3.1(–), pTRACER/CMV/BGH (Invitrogen) or
pIRESpuro/EF1a (Clontech).
Invitro digestion assay
The DNA probes for the NARPd ZFNs were constructed
by cloning a 200-bp fragment of wt mtDNA, a mtDNA
fragment containing the m.8993T>G mutation or a
fragment containing the m.8993T>C mutation into the
pCR4 vector (Invitrogen), the resulting plasmids were
named pCR4-NARP-T, pCR4-NARP-G and pCR4-
NARP-C, respectively. The DNA probes for the NCR
ZFN were constructed by cloning a 562-bp fragment
containing the human mitochondrial non-coding region
(positions 163–725 of the human mitochondrial genome)
into the pCR4 vector (Invitrogen), the resulting plasmid
was named pCR4-NCR. The above DNA plasmids were
linearized with NcoI and radioactively end-labelled using
Klenow polymerase. Probes for the experiments showed in
Figure 3 were constructed by long range PCR (the
positions of the primers are indicated in Figure 3) and
end-labelled using T7 Kinase (New England Biolabs,
Hitchin, Herts, United Kingdom).
The ZFP constructs were synthesized in the in vitro
transcription/translation reaction assay based on a reti-
culocyte lysate (Promega, Southampton, Hampshire UK)
using 10ml of lysate+1ml of each 300ng/ul DNA
template). Proteins as indicated on the ﬁgures (1ml each
or 1ml of protein and 1ml reticulocyte lysate) were
incubated (either individually or in pairs) with the 1-nM
DNA targets in 10ml of the reaction buﬀer (20mM Tris–
acetate, 50mM potassium acetate, 10mM magnesium
acetate, 1mM DTT, 100mM zinc chloride, 0.05mg/ml
BSA and 5% glycerol, pH 7.9) for 1h at 37
8C. Next, 5ml
of the reactions were loaded on a 1% agarose gel, resolved
and, after drying, subjected to autoradiography. Speciﬁc
digestion at the m.8993T>G mutation site resulted in the
formation of 2.7- and 1.5-kb DNA fragments.
Mapping thecleavage site by primer extension
In order to map the double-strand breaks introduced by
ZFNs a primer extension reaction was performed.
Unlabelled DNA probes were subjected to the in vitro
digestion assay (see above) and served as a template for
the extension reaction. The reactions were puriﬁed using
QIAquick PCR Puriﬁcation Kit (Qiagen, Crawley, Sussex,
UK) and eluted in 30ml of water. For the primer extension
20ml PCR reaction mix containing 5ml of the puriﬁed
template and 20 pmoles of 50 T7 kinase (New England
Biolabs) labelled primer were cycled 20–30 times. The
reactions were then precipitated and resolved in 4–5%
urea sequencing gels.
Maintenance, transfection and selection of
mammalian cell lines
Cell lines 143B (TK
-) and 143B (TK
-) NARP cybrids,
which contained the various percentage of the m.8993T>G
mutationintheirmtDNA(kindlydonatedbyEricSchonof
Columbia University, New York) were all grown in high-
glucose DMEM containing 2 mM L-glutamine (Gibco)
supplemented with 20% of FCS (Invitrogen). Trans-
fections of 143B (TK
-) and cybrid cells were performed
using Cell Line Nucleofector (Amaxa Biosystems,
Cologne, Germany), buﬀer kit V (Amaxa Biosystems),
plasmid DNA (1mg) puriﬁed by Qiaﬁlter MidiPrep Kit
(Qiagen) and applying programme I-13. For immunode-
tection studies zinc ﬁnger constructs were transiently
expressed for 24–36h. For FACS sorting experiments as
presented in Figure 5 and 6, cells were transfected with
appropriate pTRACER vector 48h prior to a cell sorting.
The FACS sorting using GFP as a marker was performed
asdescribed(25).Forlong-termselectionexperiments,cells
as presented in Supplementary Figure 5 cybrid cells were
transfected with appropriate pIRESpuro/EF1a vector and
24h after transfection puromycin (2mg/ml) was added and
the selective medium was replaced every 3–4 days. The cell
clones were picked up using plastic cloning cylinders
(Sigma, Gillingham, Dorset, UK).
The Flp-In TREx HEK293 cell-line (Invitrogen), used to
generate stableinducible expression ofthe ZFN constructs,
was grown in DMEM, 10% FCS (Invitrogen) supplemen-
ted with 100mg/ml Zeocin (Invivogen) and 15mg/ml
Blasticidin (Invivogen). Twenty-four hours prior to trans-
fection cells were split to 15-cm plates and grown to
80–90% conﬂuence. Flp-In TREx HEK293 cells were
transfected according to the manufacturer’s instruction
using Cell Line Nucleofector (Amaxa Biosystems), buﬀer
kit V (Amaxa Biosystems) applying programme A-23. The
pcDNA5/FRT/TO plasmid DNA encoding appriopriate
ZFNs was puriﬁed by Qiaﬁlter MidiPrep Kit (Qiagen).
Twenty four hours after transfection the selective anti-
biotics hygromycin (100mg/ml) and blasticidin (15mg/ml)
were added and the selective medium was replaced every
3–4 days. The expression was induced with the indicated
amount of doxycycline (Sigma) and medium was changed
every 2 days.
Immunodetection ofZFNs
Transiently expressed ZFNs were analysed by either
immunoﬂuorescence or immunoblotting. Adherent cells
intended for immunoﬂuorescence were grown on cover-
slips and if required, stained with Mitotracker CMX Red
(Molecular Probes, Paisley, Renfrewshire UK) added to
the culture medium for 30min in order to visualize
mitochondria. Cells were then washed in PBS and ﬁxed
3928 Nucleic Acids Research, 2008, Vol. 36, No. 12with 4% formaldehyde/PBS directly on cover slips.
Following permeabilization with 1% Triton X-100 and
washing in PBS, the ZFNs were visualized using rat
monoclonal antibody 3F10 against the HA epitope tag
(Roche, Burgess Hill, Sussex, UK). This was followed by
incubation with a secondary antibody, anti-rat IgG
conjugated to FITC (Vector, Peterborough,
Cambridgeshire). The immunoﬂuorescence was then
viewed using a Zeiss LSM 510 META confocal
microscope.
For immunoblot analysis equal amounts of proteins
corresponding to total cell lysates, protein fractions (see
below) or reticulocyte lysates were subjected to SDS–
PAGE, semi-dry transferred to nitrocellulose membranes
and incubated with speciﬁc antibodies. The blots were
further incubated with HRP-conjugated secondary anti-
bodies and visualized using ECL (Amersham, Little
Chalfont, Buckinghamshire, UK).
Cell fractionation
Mitochondria from the wt or cybrid cells were isolated as
described by Minczuk et al. (26). The mitochondrial
fractions were then incubated in 1 IB buﬀer (40 mM
Tris–HCl, pH 7.4, 25 mM NaCl and 5 mM MgCl2)
supplemented with proteinase K (BDH) at the concentra-
tions indicated in Figure 4A and B. The sub-cellular
fractions normalized for protein contents were analysed
with anti-HA mAb in order to detect ZFP protein
constructs. Blotting using antibodies against marker
proteins [anti-TFAM serum, anti-Cox2 mAb (Molecular
Probes), anti Tom22 mAb (Abcam) or anti-GAPDH mAb
(Abcam)] was also performed in order to verify the
fractions.
Measurement ofmitochondrial heteroplasmy
and mtDNA copy number
The ratio between the wt and mutant mtDNA was
measured by RFLP. Total DNA from cells was isolated
using DNasy Blood and Tissue Kit (Qiagen). A DNA
fragment corresponding to nucleotide positions 8339–9334
of the human mitochondrial genome was PCR ampliﬁed
and radioactive dCTP (GE Healthcare, Bucks,
Buckinghamshire) was added for the last cycle. The ﬁnal
PCR product was digested with SmaI recognizing a site
containing the m.8993T>G NARP/MILS mutation, and
electrophoresed in 2% agarose gels. The radioactive signal
was quantiﬁed using a phosphorimager system (GE
Healthcare).
The relative copy number of mtDNA was determined
by real-time PCR of the DNA encoding subunit 2 of
cytochrome oxidase (Cox2) using the nuclear, single-copy
gene for amyloid precursor protein (APP) as a reference.
Total cellular DNA was isolated using DNasy Blood and
Tissue Kit (Qiagen). Copy numbers of Cox2 and APP
were determined by Taqman PCR on an ABI Prism 7000
(Applied Biosystems, Foster City, CA, USA) using the
standard curve method.
RESULTS
Invitrocharacterizationofasingle-chainzincfingernuclease
With the aim of eliminating mutant mtDNA from
heteroplasmic populations of mtDNA molecules, we ﬁrst
designed a ZFN that should speciﬁcally bind and cleave a
mutated mtDNA sequence containing the m.8993T>G
mutation. In the standard ZFN conﬁguration, pairs of
ZFNs bind to adjacent DNA sequences within the target
sequence, enabling their FokI nuclease domains to
dimerize and cleave DNA selectively (16,18) (Figure 1A).
To cleave mtDNA containing the m.8993T>G mutation
we created two monomer ZFNs, one speciﬁc for the
m.8993T>G mutation and a companion ZFN that binds
upstreamofnucleotideposition8993tothecomplementary
mtDNA strand (Figure 1A). This combination should
ensurethe dimerization of the ZFN FokI nuclease domains
necessary for introducing DNA double-strand breaks
adjacent to the m.8993T>G mutation site, but not in wt
mtDNA (Figure 1A). However, under circumstances of
non-optimal expression the dimerization of the companion
ZFNs may occur, resulting in cleavage of wt mtDNA if the
speciﬁcity of the companion ZFN is insuﬃcient to prevent
homodimer formation at the target (Figure 1B). Despite
extensive investigation of more than 30 ZFN pairs
(Supplementary Data), we failed to ﬁnd a suitably active
and speciﬁc ZFN pair that would cut our speciﬁc target
sequence. Therefore, we developed an alternative approach
by designing a single-chain ZFN, in which a ZFP is linked
to two FokI catalytic domains present on a single poly-
peptide chain (Figure 1C). Such an arrangement should
enable intra-molecular association of the two FokI
domains allowing more eﬃcient DNA cleavage than with
a monomeric ZFN. By choosing a ZFP selective for the
mtDNA containing the m.8993T>G mutation it should be
possible to selectively cleave mtDNA containing this
mutation, but leave wt mtDNA unmodiﬁed (Figure 1C).
The initial single-chain ZFNs are designated as F-ZFP-
Fok-L(n)-Fok, where L(n) denotes an n-residue linker
between FokI domains (Figure 2A). The ZFP chosen,
NARPd, (Supplementary Figure 1, Top), has been shown
to bind selectively to the m.8993T>G sequence (data not
shown). This ZFP was linked to the mitochondria tar-
geting sequence from human ATP synthase F1b subunit
(denoted F) at its N-terminus and a HA tag and a nuclear
export sequence (NES) at its C-terminus [previously we
have shown that a NES greatly assists in the delivery of
ZFPs to mitochondria in cells (19)]. The C-terminus was
fused to a FokI domain via a ﬂexible linker and in turn
this FokI domain was linked to a second FokI domain by
ﬂexible linkers of various lengths (Figure 2A).
To cleave DNA eﬃciently the linker between the two
FokI domains must allow them to form an intra-mole-
cular quasi-dimer. To optimize linker length we tested the
eﬀects of six diﬀerent linker lengths on in vitro cleavage of
a DNA target, pCR4-NARP-G, containing the
m.8993T>G substitution (Figure 2B and C). Linkers of
35 or more amino acids gave almost complete cleavage
(Figure 2C, lines 7 and 8). In contrast, cleavage of the
same DNA substrate with the F-NARPd-Fok monomer
was much less eﬃcient, and even increasing the incubation
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mutant mtDNA
(m.8993T>G mutation)
wt mtDNA
mutant mtDNA
(m.8993T>G mutation)
FokI CD
FokI CD
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wt mtDNA
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Figure 1. Interactions of ZFNs with wt and mutated mtDNA. The sequence surrounding the m.8993T>G mutation in mtDNA was used to
exemplify targeting of pathogenic mitochondrial mutations by ZFNs. The changed base at position 8993 is indicated in yellow. DNA cleavage is
marked by the green scissors symbol. (A) Schematic diagram of ZFN heterodimer in the standard conﬁguration bound to the mutated mtDNA target
(upper). Each of the monomeric ZFN consists of the FokI nuclease domain linked to a ZFP. One of the ZFNs (red) was designed to bind to the
mutated mtDNA site, whereas its companion ZFN binds a native sequence on the opposite DNA strand (blue). In the case of wt mtDNA (lower)
mutation-speciﬁc ZFN does not bind the target therefore precluding a formation of a heterodimer and DNA cleavage. (B) Schematic diagram of the
partner ZFN (blue) bound to the wt sequence and producing DNA cleavage by dimerization with another copy of the same construct non-speciﬁcally
bound to mtDNA when the mutation-speciﬁc ZFN (red) is not bound. This outcome is undesirable when a mutation is targeted in heteroplasmic
population of mtDNA molecules. (C) Schematic diagram of ‘single-chain ZFN’ consisting of two FokI nuclease domains tethered together by a long
protein linker and fused to a ZFP. The ZFP is designed to bind exclusively to the mutated mtDNA site; therefore, only mtDNA molecules
harbouring this mutation are cleaved (upper) while the wt copies are spared (lower).
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not shown). DNA cleavage by F-ZFP-Fok-L(n)-Fok was
speciﬁc for the m.8993T>G substitution (pCR4-NARP-
G) as DNA substrates harbouring T or C instead of G in
this position (pCR4-NARP-T or pCR4-NARP-C, respec-
tively) were not cleaved by any of the F-NARPd-Fok-
L(n)-Fok constructs (Figure 2C).
To obtain additional insight into the speciﬁcity of the
F-ZFP-Fok-L(n)-Fok nucleases, the two most active
constructs, with 35 and 40 amino acid linkers, were
tested in vitro with two large DNA molecules (9176 and
8776 bp), that covered the entire human mtDNA sequence
and both of which contained the m.8993T>G mutation
(Figure 3A). Incubation of these DNA molecules with
F-NARPd-Fok-L35-Fok (Figure 3A, line 3) or
F-NARPd-Fok-L40-Fok (Figure 3A, line 4) resulted in
digestion products of 350 or 330 bp that corresponds
to DNA cleavage at the m.8993T>G mutation sites.
Cleavage generates a small product ( 350 or 330 bp),
and also a large product ( 8820 or 8450 bp) slightly
smaller than the starting material that is not separated
from the starting material by this gel system. Thus,
F-NARPd-Fok-L35-Fok and F-NARPd-Fok-L40-Fok
only cleave DNA at the site of the m.8993T>G mutation,
leaving the rest of the wt mtDNA genome unaltered.
Primer extension experiments performed on the DNA
digested by these nucleases showed that the DNA double-
strand breaks occur 2–7 bp upstream from the ZFP-
binding site (Figure 3B, lines 3 and 4), consistent with the
binding position of the nuclease relative to the ZFP-
binding site. Therefore, we have successfully constructed a
single-chain ZFN that selectively cleaves mutated, but not
wt, mtDNA.
Localization of single-chain ZFNs to mitochondria
within cells
The MTS and NES on F-ZFP-Fok-L(n)-Fok should
ensure their eﬀective localization to mitochondria in cells
(19). To see if this was the case, we studied the distribution
of F-NARPd-Fok-L35-Fok within 143B cells and com-
pared it to its monomeric counterpart F-NARPd-Fok.
To see if these proteins were localized within mitochon-
dria, we transiently expressed them and then fractionated
the cells into diﬀerent compartments (Figure 4A and B).
Both ZFNs were present in the mitochondrial fraction and
the MTS was cleaved oﬀ from the precursor protein (p)
leaving the mature (m) protein, consistent with uptake
0%
20%
40%
60%
80%
100%
18
B
A
22 27 32 35 40 f.p. -
F-NARPd-Fok-L(n)-Fok
digested pCR4-N ARP-G  p robe
4.2
1.5
2.7
[kb]
4.2
1.5
2.7
4.2
1.5
2.7
pCR4-NARP-G
pCR4-NARP-T (wt)
pCR4-NARP-C
=n [aa]
C
18 22 27 32 35 40 n=
[aa] F-NARPd-Fok-L(n)-Fok
MTS F ZFP HA FokI CD NES
flexible
linker
([SGGGG]3SS)
F-ZFP-Fok-L(n)-Fok
FokI CD
flexible linkers
of various
lengths
(n=18–40 aa)
18 22 27 32 35 40 -
F
-
N
A
R
P
d
-
F
o
k
-
L
L
F-NARPd-Fok-L(n)-Fok
=n [aa]
D
anti-HA
012345678
12345678
-
-
-
75
50
37
[kDa]
0 0 0 2 12 75 97 19 59 5
percentage
of cleavage
F
-
N
A
R
P
d
-
F
o
k
-
L
L
Figure 2. Designing a single-chain ZFN to target a mitochondrial point
mutation. (A) Schematic structure of mitochondrially targeted single-
chain nucleases. The mitochondrial targeting sequence of F1b subunit of
mitochondrial ATP synthase (MTS F) was fused to the N-terminus of the
ZFP. The HA epitope tag and the NES facilitating mitochondrial
targeting were added to the C-terminus of the ZFP. Two FokI domains
were fused on the C-terminus of the ZFP and linked together via ﬂexible
linkers of various lengths denoted L(n), where n is the length of the linker
in amino acids. (B) Optimization of the single-chain ZFN based on the
NARPd construct (see Figure 1C). Variants of F-NARPd-Fok-L(n)-Fok
were subjected to the in vitro assay as described in Materials and methods
section using the speciﬁc target DNA in order to determine the optimal
length of the linker between the two tethered FokI domains. The plot
shows the results of the assay performed three times. (C) In vitro cleavage
assay testing the speciﬁcity of the F-NARPd-Fok-L(n)-Fok constructs.
The assay was performed as described in Materials and methods section.
The following probes have been used: pCR4-NARP-G—containing the
m.8993T>G substitution, pCR4-NARP-T —wt (i.e ‘T’) at the 8993
position and pCR4-NARP-C— containing the m.8993T>C substitution.
The f.p denotes free probe. Speciﬁc digestion at the m.8993T>G mutation
site results in the formation of 2.7- and 1.5-kb DNA fragments. The
percentage of cleavage of the pCR4-NARP-G probe is given in the top
panel. (D) Western blot illustrating that the constructs used in the test
above are produced with the same eﬃciency in the in vitro transcription/
translation system. ZFNs were detected with anti-HA antibody.
Nucleic Acids Research, 2008, Vol. 36, No. 12 3931through the conventional mitochondrial import pathway.
To determine where within mitochondria the proteins
were located, the isolated mitochondria were incubated
with proteinase K. The mature forms of F-NARPd-Fok
(Figure 4A) and F-NARPd-Fok-L35-Fok (Figure 4B)
were protected from proteolysis, to the same extent as the
mitochondrial matrix protein TFAM (27), while a protein
associated with the mitochondrial outer membrane
(Tom22) (28) and one associated with the inner membrane
(Cox2) were progressively degraded over time by protein-
ase K (Figure 4A and B). To further conﬁrm the
mitochondrial localization of F-NARPd-Fok-L35-Fok
and F-NARPd-Fok, we carried out immunoﬂuorescence
experiments on the cells. The location of the proteins
within cells was visualized using an antibody against the
HA tag, and co-staining with the mitochonodrial probe
Mitotracker-RED showed that these proteins were present
mainly in mitochondria (Figure 4C). Together, these data
indicate that both proteins F-NARPd-Fok-L35-Fok and
F-NARPd-Fok are present in the mitochondrial matrix
within cells.
Mitochondria-targeted specific ZFNs cleave wt
mtDNA incells
We have shown that F-NARPd-Fok-L(n)-Fok constructs
are taken up by mitochondria in cells and can selectively
cleave their target mtDNA sequence in vitro. However, the
mtDNA environment in vivo is quite diﬀerent from that
in vitro and therefore it is important to conﬁrm that
F-ZFP-Fok-L(n)-Fok constructs can cleave mtDNA
within mitochondria inside cells. To assess this, we used
a F-ZFP-Fok-L(n)-Fok with a ZFP against a sequence in
the wt mtDNA non-coding region (NCR) that enabled us
to test the eﬃcacy of the F-ZFP-Fok-L(n)-Fok at cleaving
mtDNA in cells containing only wt mtDNA. We
constructed a F-NCR-Fok-L35-Fok designed to cleave a
sequence in the control region of wt mtDNA, as well as its
monomeric form, F-NCR-Fok, that should bind to the
same sequence. The speciﬁcity of cleavage of the mtDNA
target sequence was tested in the in vitro assay as above
and ZFN F-NCR-Fok-L35-Fok almost completely
cleaved the speciﬁc DNA target, while its monomeric
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Figure 3. The speciﬁcity of single-chain ZFNs designed to target the mitochondrial point mutation. (A) In vitro assay verifying the speciﬁcity of the
F-NARPd-Fok-L35-Fok (line 3) and F-NARPd-Fok-L40-Fok (line 4) constructs to a single site in human mtDNA. The assay was performed
similarly to the experiment shown in Figure 2. The DNA probes used here though were generated in a long-range PCR reaction so that the two
resulting products represented the entire mtDNA molecule harbouring the m.8993T>G substitution (grey curved bars with the mtDNA coordinates
given on each end). The PCR products were radioactively labelled using T4 Kinase. (B) Mapping the main cleavage sites of F-NARPd-Fok-L35-Fok
and F-NARPd-Fok-L40-Fok constructs by primer extension. Unlabelled DNA probes (as described above) were subjected to the in vitro digestion
assay with F-NARPd-Fok-L35-Fok (line 3) or F-NARPd-Fok-L40-Fok (line 4). Next the digested DNA served as a template for the extension
reaction of the 5’ labelled primer that anneals 100-bp upstream from the NARPd-binding site. DNA strand breaks introduced by F-NARPd-Fok-
L35-Fok or F-NARPd-Fok-L40-Fok map to several sites 2–7-bp upstream from the NARPd-binding site.
3932 Nucleic Acids Research, 2008, Vol. 36, No. 12counterpart, F-NCR-Fok, cleaved the same target with
 15% eﬃciency (Supplementary Figure 3). Cellular
localization of F-NCR-Fok and F-NCR-Fok-L35-Fok
was mitochondrial as shown by imunocytochemistry and
subcellular fractionation (data not shown).
In order to see if F-NCR-Fok-L35-Fok cleaved wt
mtDNA in cells, tetracycline-inducible HEK293 TREx
cell lines expressing F-NCR-Fok and F-NCR-Fok-L35-
Fok were constructed. Induction of the single-chain ZFN
F-NCR-Fok-L35-Fok resulted in a rapid and almost com-
plete loss of mtDNA after 2 days, consistent with the rapid
cleavage of wt mtDNA (Supplementary Figure 4).
Expression of the F-NCR-Fok monomer also signiﬁcantly
decreased mtDNA copy number, but to alesser extent than
the single-chain ZFN, consistent with its lower nuclease
activity in vitro (Supplementary Figure 4). Therefore, when
expressed in cells mitochondria-targeted single-chain ZFN
is capable of binding and cleaving mtDNA.
Selective depletion of mutated mtDNA molecules in
heteroplasmic cellsby amitochondrially targetedZFN
As shown in vitro, F-NARPd-Fok-L35-Fok can selectively
degrade mutated mtDNA, while leaving wt mtDNA uncut,
and it is readily taken up by mitochondria in cells. Further-
more, a related F-ZFP-Fok-L35-Fok designed to bind to
wt mtDNA was active within mitochondria in cells, as
indicated by the depletion of mtDNA. Therefore, within
heteroplasmic cells F-NARPd-Fok-L35-Fok should selec-
tively degrade mutated but not wt mtDNA and thereby
decrease the proportion of mutated mtDNA molecules
in a cell.
As observed for F-NCR-Fok, a mitochondrially tar-
geted monomeric ZFN was also capable of depleting
mtDNA in cells even when present without a binding
partner. Thus, ZFN monomers designed to bind mutated
DNA sites, could to some extent eliminate mutant
mtDNA. Therefore, in subsequent experiments we com-
pared monomeric F-ZFN-Fok with the single-chain ZFN
with a quasi-dimeric FokI domain, to determine which
conﬁguration is most eﬀective.
To assess eﬃciency of cleavage, we used heteroplasmic
cybrid cells containing 90% of mtDNA molecules with
the m.8993T>G mutation (the term cybrid refers to a
clonal cell line resulting from the fusion of heteroplas-
mic cells bearing mutated mtDNA derived from patients
with mtDNA-less cells). Plasmids with a puromycin-
selectable marker expressing F-NARPd-Fok-L35-Fok or
the F-NARPd-Fok were used to transfect cells, which were
grown for 10 days using puromycin to ensure retention of
the transgene. Clones derived from individual transfected
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Figure 4. ZFNs are localized in mitochondria in cells. (A) and (B) The
F-NARPd-Fok and F-NARPd-Fok-L35-Fok ZNFs localize inside
mitochondria. The 143B cells harbouring wt mtDNA were transiently
transfected with monomeric F-NARPd-Fok (A) or single-chain ZFN—
F-NARPd-Fok-L35-Fok (B), fractionated 48h post-transfection and the
protein fractions were analysed by western blotting using anti-HA mAb.
ThelocalizationoftheZFNprecursors(‘p’)andtheirmature(‘m’)formin
total cell lysate (‘T’), cytosolic (‘C’) and a mitochondrial fraction treated
with proteinase K under various conditions as indicated, was compared
with the localization of marker proteins. The precursors of mitochondrial
ZFNs, found in the mitochondrial fractions, were located outside the
mitochondria,sincetheywereaccessibletoproteasedigestion.Incontrast,
the mature form of ZFNs was protected and became accessible to
proteolysis only after the mitochondria were lysed with Triton X-100. The
following endogenous proteins were used as fractionation markers:
(i) TFAM: the transcription factor that is localized in the mitochondrial
matrix; (ii) Cox2; a subunit of the cytochrome oxidase complex localized
in the mitochondrial inner membrane; (iii) Tom22: a subunit of
mitochondrial translocase of outer membrane; and (iv) GAPDH: a
protein localized in cytoplasm. (C) The F-NARPd-Fok and F-NARPd-
Fok-L35-Fok ZFNs co-localize with mitochondria. The intra-cellular
localizationofZFNs wasadditionallyanalysed byimmunoﬂuorescence in
transiently transfected 143B cells. ZFNs were detected with antibodies
against the HA epitope-tag followed by secondary antibodies conjugated
to FITC (1 and 4; green) Mitochondria were stained with MitoTracker
CMX Red (2 and 5; red). Both ZFNs exhibited mitochondrial-staining
patternthatinrepresentedbyyellowstainingondigitallyoverlaidpictures
(3 and 6).
Nucleic Acids Research, 2008, Vol. 36, No. 12 3933cells were then isolated and the percentage of the wt
mtDNA was assessed for each clone using PCR/RFLP.
Those clones transfected with F-NARPd-Fok-L35-Fok
had signiﬁcantly higher levels of wt mtDNA compared to
the mock transfected controls or to those transfected with
the F-NARPd-Fok monomer (Supplementary Figure 5).
Some clones transfected with the F-NARPd-Fok-L35-Fok
ZFP-single-chainnucleasehad40%wtmtDNA, compared
to5–20%in thecontrols.Transfection withtheF-NARPd-
Fok monomer did not increase wt mtDNA content to a
statistically signiﬁcant extent. However, by 14 days post-
transfection none of the clones initially transfected with
F-NARPd-Fok or F-NARPd-Fok-L35-Fok expressed the
protein at detectable levels and the number of clones that
survived selection was much lower for the ZFN constructs
than for the control. This suggests a possible growth
disadvantage associated with a prolonged mitochondrial
expression of these ZFNs under conditions that led to loss
of the corresponding plasmid DNA over time. Even so, the
increased proportion of wt mtDNA in the transfected cells
was promising, and suggested that expression of the
transgene initially led to the selective depletion of mutated
mtDNA that was retained, even after the transgene was no
longer expressed in those cells.
As experiments with F-NCR-Fok-L35-Fok showed
rapid depletion of mtDNA with a maximum eﬀect evident
after 2 days, prolonged expression of mitochondrial ZFNs
should not be necessary to deplete mtDNA. Therefore, we
next assessed the changes in heteroplasmy that occurred
over 2 days post-transfection in heteroplasmic cybrid cells
containing 85% of the m.8993T>G mutation. For these
experiments, the F-NARPd-Fok or F-NARPd-Fok-L35-
Fok constructs were co-expressed with GFP encoded by
the same vector. This enabled us to enrich the population
of F-NARPd-Fok or F-NARPd-Fok-L35-Fok expressing
cells by FACS sorting using GFP as a marker. The levels
of wt mtDNA in the cells enriched for F-NARPd-Fok or
F-NARPd-Fok-L35-Fok 2 days after transfection were
then measured by PCR/RFLP. The F-NARPd-Fok-L35-
Fok transfected cells, but not those transfected with
F-NARPd-Fok, showed signiﬁcantly higher levels of wt
mtDNA as compared to the mock-transfected controls in
three independent experiments (Figure 5B). The total
mtDNA copy number in the F-NARPd-Fok or
F-NARPd-Fok-L35-Fok transfected and FACS sorted
cells was also lowered compared to controls by  40% and
 60%, respectively (Figure 5C). The drop in the mtDNA
level for F-NARPd-Fok-L35-Fok was consistent with the
selective removal of mutated mtDNA. Initially the cells
contained 15% wt and 85% mutated mtDNA; if the 40%
decrease in mtDNA copy number was due exclusively to
loss of mutated mtDNA the cell would then contain 25%
wt mtDNA, close to what was found. In contrast, the
decrease in mtDNA copy number caused by F-NARPd-
Fok was greater than expected from the selective removal
of the mutant mtDNA. If loss of 60% of the wt mtDNA
was due exclusively to loss of mutated mtDNA then we
would expect 37.5% wt mtDNA, instead we found 20%,
perhaps implying an non-speciﬁc interaction of the
mononmeric ZFN with the wt mtDNA in these experi-
ments. The number of GFP positive cells was much lower
for F-NARPd-Fok or F-NARPd-Fok-L35-Fok trans-
fected cells compared with the mock-transfected controls,
implyingageneralcytotoxiceﬀectofZFNexpressionatthe
dose levels tested (Supplementary Table 1). To test whether
the shift in heteroplasmy observed above was simply
caused by this non-speciﬁc eﬀect of ZFN expression in
mitochondria, we transiently expressed the F-NCR-Fok-
L35-Fok or F-NCR-Fok constructs in heteroplasmic
cybrid cells containing 85% of the m.8993T>G mutation.
As these constructs are speciﬁc for the mtDNA non-coding
region, they should aﬀect mutated and the wt mtDNA
molecules to the same extent. As before, cells expressing
F-NCR-Fok or F-NCR-Fok-L35-Fok were enriched by
FACS sorting using GFP as a marker, 2 days after trans-
fection. In this case, the ratio between the mutant and the
wt mtDNA was unaltered by expression of the ZFNs
(Figure 5D). As expected, the mtDNA copy number was
signiﬁcantly lowered compared to mock-transfected con-
trols(Figure5E)andwithrespecttotheNARPdconstructs
(Figure 5C). This is consistent with elimination of both the
wt and mutated mtDNA by the F-NCR-Fok or F-NCR-
Fok-L35-Fok and indicates that the increased proportion
of wt mtDNA upon expression of F-NARPd-Fok-L35-
Fok was a speciﬁc eﬀect due to the selective elimination of
the mutated mtDNA.
We next investigated whether the changes in hetero-
plasmy caused by the F-NARPd-Fok-L35-Fok were stable
and whether the removal of the mutant mtDNA by ZFNs
observed in the ﬁrst 48h can be maintained over an
extendedperiod.Todothis,heteroplasmiccybridscontain-
ing 85% of the m.8993T>G mutation were transiently
transfected with F-NARPd-Fok or F-NARPd-Fok-L35-
Fok as described above and isolated by FACS sorting 2
days post-transfection. These cells were then grown in a
high-glucose medium without any selection pressure to
retain the plasmids coding for ZFNs and under these
conditions the plasmids were lost within 1–3 days (3–5 days
post-transfection). The level of wt mtDNA and the
mtDNA copy number were then measured 2 and 30 days
post-transfection. The elimination of mutated mtDNA
detected 2 days after transfection with the F-NARPd-Fok-
L35-Fok constructwasmaintained atalmostthe samelevel
after 30 days (Figure 6B). Most interestingly, the mtDNA
copy number in the transfected cells that had been lowered
2 days post-transfection was restored to 80–90% of control
levels at 30 days (Figure 6C), while retaining the higher
proportion of wt mtDNA.
The level of wt mtDNA in cybrids was additionally
assessed in clones derived from single cells isolated by
FACS sorting and then grown for 30 days. The average
level of wt mtDNA in ten randomly selected clones
(Figure 6D) was similar to that in the bulk population
(Figure 6B). Three out of the 10 clones transfected with
the F-NARPd-Fok-L35-Fok construct had >40%wt
mtDNA.
DISCUSSION
The diﬃculties of developing therapies for mitochondrial
diseases have led to the development of mitochondrial
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Figure 5. Mitochondrial heteroplasmy in cells expressing mutation-speciﬁc ZFNs. The m.8993T>G mutation-speciﬁc or control ZFNs were
co-expressed with eGFP from a single vector in heteroplasmic cybrid cells containing  85% of mtDNA molecules with the NARP m.8993T>G
mutation (dashed line). Two days post-transfection, cells were FACS sorted using eGFP as a marker and the degree of heteroplasmy was assessed
in the sorted cells. Mock indicates cells transfected with vector alone. Symbols:  P<0.05;   P<0.01 in two-tailed t-test, unequal variance.
(A) Schematic illustration of the experimental approaches taken. (B) Diﬀerences in the proportion of the wt and mutant mtDNA in cells transfected
with F-NARPd-Fok or F-NARPd-Fok-L35-Fok speciﬁc for the m.8993T>G. The result is an average of three independent experiments. The
diﬀerence between mock and F-NARPd-Fok-L35-Fok transfected cells is highly signiﬁcant (P=0.015), while the diﬀerence between mock and
the F-NARPd-Fok monomer is not signiﬁcant (P=0.2). (C) Total (sum of mutant and wt) mtDNA copy number in the cells transfected with the
m.8993T>G mutation-speciﬁc ZFNs expressed in arbitrary units (a.u.). The results are normalized to mock-transfected cells. (D) Diﬀerences in the
proportion of the wt and mutant mtDNA in cells transfected with F-NCR-Fok or F-NCR-Fok-L35-Fok targeting a site in the mitochondrial
non-coding region. The result is an average of three independent experiments. No statistically signiﬁcant diﬀerences between the constructs have been
found. (E) Total mtDNA copy number in the cells transfected with the mitochondrial NCR-speciﬁc ZFNs expressed in arbitrary units (a.u.).
The results are normalized to mock-transfected cells.
Nucleic Acids Research, 2008, Vol. 36, No. 12 3935genome-targeted strategies to selectively deplete mutated
mtDNA molecules from cells and thereby enable the wt
mtDNA molecules to re-populate the cell (3,4). The
selective degradation of mutated mtDNA molecules has
been achieved by targeting restriction enzymes to mito-
chondria, but these are limited to the small number of
sequencesthatarepresentinmutatedbutnotinwtmtDNA
molecules and for which an RE is available. To overcome
this limitation we developed mitochondria-targeted ZFNs
in order to speciﬁcally target a mutated mtDNA for
degradation. Initial attempts were made using the conven-
tional conﬁguration of heterodimeric ZFNs (Figure 1A),
where one monomer binds a mutated mtDNA sequence
while its partner binds an adjacent wt sequence enabling
dimerization between two FokI domains to cleave dsDNA
between the ZFPs-binding sites. However, this approach
has a number of potential limitations to its applicability to
targeting mutated mtDNA molecules. First, one of the
monomers must bind very selectively to a sequence
diﬀering from the wt sequence by a single base pair out of
9–12 bp. Second, a heterodimeric ZFN designed to target a
mtDNA mutation could lead to the monomer that binds a
wt sequence forming an active nuclease that cleaves a wt
mtDNA molecule if the speciﬁcity of this ZFN was
insuﬃcient to prevent homodimer formation at the target
(Figure 1B). Consistent with this, we frequently observed
cleavage of wt mitochondrial targets by ZFN monomers
in vitro (Supplementary Figure 2), and a rapid mtDNA
depletion was observed when mitochondrially targeted
monomeric ZFN binding to the mtDNA NCR was
expressed in normal (Supplementary Figure 5B) and
mutant cells (Figure 5E) under our experimental
conditions.
To address these concerns, we constructed and char-
acterized a single-chain ZFN, in which a zinc ﬁnger peptide
is linked to two FokI catalytic domains that are present on
a single polypeptide. Unlike a heterodimeric ZFN that
usually recognizes 24 bp (12 bp by each monomer), our
single-chain ZFN only recognizes 12 bp. However, this
lower speciﬁcity is suﬃcient for targeting sites in human
mtDNA as the genome is only 16.5 kb making it unlikely
that identical 12-bp binding sites exists more then once in
mtDNA (statistically a 12-bp-long sequence would be
present once per 1.68 10
7 bp). Our novel construct of a
ZFP conjugated to two FokI catalytic domains allows for
correct dimerisation of the catalytic domains and forma-
tion of an active nuclease that is far more eﬃcient in vitro
than its counterpart with only one FokI domain.
Furthermore, within mitochondria in heteroplasmic cells
(Supplementary Figure 5 and Figure 5), a mitochondrially
targeted single-chain ZFN was also far more eﬃcient in
cleavingthemutatedsequencethanthenucleasecontaining
a single FokI domain. However, there was some cleavage
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Figure 6. Stable shift in mitochondrial heteroplasmy in cells expressing
mutation-speciﬁc ZFNs. The m.8993T>G mutation-speciﬁc ZFNs,
F-NARPd-Fok or F-NARPd-Fok-L35-Fok, were co-expressed with
eGFP from a single vector in heteroplasmic cybrid cells containing
 85% of mtDNA molecules with the NARP m.8993T>G mutation
(dashedline).TwodaysafterthetransfectioncellswereFACSsortedusing
eGFP as a marker, then the sorted cells were grown on non-selective
medium for a further 28 days. The percentage of mutant mtDNA was
assessed again at 2 and 30 days. Mock indicates cells transfected with
vector alone. Symbols:  P<0.05;   P<0.01 in two-tailed t-test, unequal
variance. (A) Schematic illustration of the experimental approaches taken.
(B) Diﬀerences in the proportion of the wt and mutant mtDNA in bulk
population of transfected cells at 2 and 30 days. The diﬀerence between
mockandF-NARPd-Fok-L35-Foktransfectedcellsafter30daysishighly
signiﬁcant (P=0.007), whereas the diﬀerence between mock and the
F-NARPd-Fok monomer is not signiﬁcant (P=0.54). (C) Total mtDNA
copy number in the transfected cells measured at 2 and 30 days expressed
in arbitrary units (a.u.). The results are normalized to mock transfected
cells. (D) Diﬀerences in the proportion of the wt and mutant mtDNA in
individual clones, randomly picked at 30 days post-transfection. The red
horizontal bar indicates an average value for each construct. The
diﬀerence between mock and F-NARPd-Fok-L35-Fok transfected cells
after30daysishighlysigniﬁcant (P=0.003),thediﬀerencebetweenmock
and the F-NARPd-Fok monomer is of much lower signiﬁcance (P = 0.4).
3936 Nucleic Acids Research, 2008, Vol. 36, No. 12by the monomer, presumably due to cross-dimerization
between DNA-bound and free F-NARPd-Fok. The ability
of a single-chain quasi-dimeric ZFN to generate ds DNA
breaks opens up the possibility of designing speciﬁc ZFNs
without a need for generating pairs of ZFNs. This
signiﬁcantly simpliﬁes design and could be particularly
useful for targeting unique sequences in relatively short
genomes, such as in organelles, bacteria or viruses.
Furthermore, our novel design allows for generation of
nucleases with novel speciﬁcities that could be used in
standard in vitro laboratory tests such as RFLP.
Previous studies indicated that cellular expression of
non-optimized ZFNs can be associated with signiﬁcant
cytotoxicity due to cleavage at oﬀ-target sites (29,30).
Consistent with this possibility, the expression of the ZFN
constructs (both monomeric and single-chain dimers)
used in this study was associated with cytotoxic eﬀects.
Although in order to minimize general cytotoxicity linked
to generation of nuclear DNA breaks, we equipped
mitochondrially targeted ZFNs with the nuclear export
signal (NES), it may be that the NES used is not fully
eﬀective and it may be necessary to minimize cytotoxicity
by using a tightly regulated expression system or by
optimizing the NES. Other ways of lowering the cytotox-
icty of ZFNs could be the optimization of the ZFP protein
sequence (18).However,toxicityassociatedwithprolonged
over-expression is not a major barrier to this ZFN
technology, because it causes a permanent change at the
DNA level. This was shown by the fast shift in the
heteroplasmy observed 2 days after the transfection of a
mutation-speciﬁc ZFN was maintained at the same level
for a further 28 days (Figure 6). Therefore, long-term
exposuretoaZFNshouldnotbenecessarytobringabouta
phenotypic change, in contrast to engineered ZFP tran-
scription factors. This may be particularly relevant for the
elimination of mutated mtDNA from heteroplasmic cells,
which require only a certain threshold proportion of wt
mtDNA to be reached in order to restore the phenotype.
In summary, here we have demonstrated that selective,
single-chain quasi-dimeric ZFN can be generated. When
single-chain ZFNs speciﬁc for a pathogenic point muta-
tion in mtDNA were targeted to mitochondria in hetero-
plasmic cells harbouring mutated mtDNA there was
selective elimination of the mutated mtDNA and the
proportion of wt mtDNA in these cells increased.
Therefore, ZFN technology may prove useful in the
therapeutic manipulation of heteroplasmy in the treat-
ment of mtDNA diseases.
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